PZ703b (TFA)

PZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research[1][2].

Product Specifications

UNSPSC

12352005

Target

Bcl-2 Family; PROTACs

Type

Reference compound

Related Pathways

Apoptosis; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pz703b-tfa.html

Purity

98.62

Solubility

10 mM in DMSO

Smiles

ClC1=CC=C(C=C1)C2=C(C[C@](CNC(CCCCCCCCC(N[C@H](C(N3C[C@@H](C[C@H]3C(N[C@@H](C)C4=CC=C(C=C4)C5=C(N=CS5)C)=O)O)=O)C(C)(C)C)=O)=O)(CC2)C)CN6CCN(CC6)C7=CC=C(C=C7)C(NS(C8=CC(S(=O)(C(F)(F)F)=O)=C(C=C8)N[C@H](CCN9CCOCC9)CSC%10=CC=CC=C%10)(=O)=O)=O.OC(C(F)(F)F)=O

Molecular Formula

C82H103ClF6N10O13S4

Molecular Weight

1714.46

References & Citations

[1]Yi Xu, et al. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun. 2022 Oct 1;623:120-126. |[2]Pratik Pal, et al. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. J Med Chem. 2021 Oct 14;64 (19) :14230-14246.